Company intelligence / Profile preview

BioSenic

Mont-Saint Guibert, Belgiumbiosenic.com ↗

Ownership: Private
Development stage: Other

Overview

BioSenic has demonstrated positive Phase II results with its arsenic trioxide plus prednisone combination in cGVHD, showing a 75% overall response rate at 6 months. The ALLOB allogeneic cell therapy is in Phase II for orthopedic indications, while PREOB autologous cell therapy is in Phase III for osteonecrosis and non-union fractures. A pivotal Phase III trial of oral arsenic trioxide ("OATO"/"ArsciCor") as first-line treatment for cGVHD is being prepared following a positive FDA PreIND meeting

Therapeutic areas: NeurologyImmunologyRheumatologyOther
Modalities: Small molecule (arsenic trioxide)Cell therapyAllogeneic cell therapyAutologous cell therapyRecombinant protein (for bone regeneration products)
Industry: Biotech

Drug pipeline

5 assets

JTA-004

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioSenic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSenic.

Explore the full profile